Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer
Date
2018-05
Journal Title
Journal ISSN
Volume Title
Publisher
Citation
Hill, A G, Findlay, M, Burge, M, Jackson, C, Garcia Alfonso, P, Samuel, L, Ganju, V, Karthaus, M, Amatu, A, Jeffrey, M, Di Bartolomeo, M, Bridgewater, J, Coveler, A, Hidalgo, M, Kapp, A, Sufan, R, McCall, B, Hanley, W, Penuel, E, Pirzkall, A & Tabernero, J 2018, 'Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer', Clinical Cancer Research, vol. 24, no. 10, pp. 2276-2284. https://doi.org/10.1158/1078-0432.CCR-17-0646